Company Overview of Arch Therapeutics, Inc.
Arch Therapeutics, Inc., a life sciences company, develops a solution to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. It specializes in products based on a self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. The company's product, AC5, is an hemostatic agent and synthetic peptide comprising naturally occurring amino acids that controls bleeding and leakage during surgery and trauma. Arch Therapeutics, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2006
Key Executives for Arch Therapeutics, Inc.
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2012.
Arch Therapeutics, Inc. Key Developments
Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan
Oct 7 13
Arch Therapeutics, Inc. announced that the Massachusetts Life Sciences Center has concluded the requisite steps to award Arch with a $1 million Accelerator Loan. The Accelerator Loan Program, the Center's investment program, supports companies by providing loans of up to $1 million that will match grants and investments from the federal government, foundations, non-profit agencies, institutional investors, and other sources of capital. By leveraging other sources of capital, the Accelerator Loan Program will provide support that enables companies to conduct vital research and development and attract subsequent investment, improving the odds of bringing cutting-edge innovation to the marketplace. To date, the Center has funded 24 companies through this program.
Arch Therapeutics, Inc. Announces to Develop Products That Make Surgery and Interventional Care Faster and Safer
Jul 30 13
Arch Therapeutics, Inc. is developing products that make surgery and interventional care faster and safer by utilizing a novel approach to stop bleeding (referenced as "hemostasis"), control leaking (referenced as "sealant"), and provide other advantages during surgery and trauma care. AC5 is based on a self-assembling peptide solution that creates a physical, mechanical barrier, which could be applied to bleeding organs or wounds to seal leaking blood and other fluids. To date, the company have devoted much of the work on core technology to selecting the lead product composition, conducting initial safety and efficacy tests, developing reproducible and reliable analytical and manufacturing methods, and scale-up. The company have also focused on developing relevant intellectual property rights via filing several patent applications in multiple jurisdictions for self-assembling peptides and methods of use thereof, all of which are pending. Much of this pre-clinical work is a necessary pre-requisite to the clinical-regulatory program, which the company are currently designing. The results of early data from preclinical tests have shown that AC5 achieves hemostasis quickly and effectively. AC5(can be directly applied as a liquid or sprayed, making it user-friendly and able to conform to irregular wound geometry, and is not sticky or glue-like, making it ideal for use in the setting of minimally invasive laparoscopic surgeries. Further, AC5 is transparent, which should make it easier for surgeons or other healthcare providers to maintain a clear field of vision during a surgical procedure and prophylactically stop bleeding as it starts, which the company call Crystal Clear Surgery. In the preclinical tests conducted to date, AC5 as demonstrated improved average time to hemostasis during a range of surgical procedures compared to TTH when using a control substance, a saline control substance, a control peptide, and a cautery control substance during those same procedures. The results of those tests have shown a TTH of under 15 seconds when AC5 was applied, compared to a TTH ranging from 80 to 300 seconds when various control substances were applied, depending on the nature of the control substance and procedure performed. To date, the company have noted no ill effects or other adverse consequences.
Arch Therapeutics, Inc. Presents at The Rodman & Renshaw Annual Global Investment Conference, Sep-10-2013 08:45 AM
Jul 30 13
Arch Therapeutics, Inc. Presents at The Rodman & Renshaw Annual Global Investment Conference, Sep-10-2013 08:45 AM. Venue: Millennium Broadway Hotel, 145 W 44th St., New York, New York, United States. Speakers: Terrence W. Norchi, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 30, 2013
June 19, 2013
April 25, 2013